Mary Leary, DO
Family Medicine · Eagleville, PANPI 1104810860
Payments from drug & device makers
Across 769 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- Amgen$1K
- Pfizer$963
- Lilly USA, LLC$882
- Amarin Pharma, Inc.$856
- plus $5K from 29 others
What the payments were for
- Food & beverage$12,12499%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 150 | $1,900 |
| AbbVie(2 entities) | 75 | $1,296 |
| Amgen | 52 | $1,203 |
| Pfizer | 60 | $963 |
| Lilly USA, LLC | 65 | $882 |
| Amarin Pharma, Inc. | 57 | $856 |
| AstraZeneca | 54 | $840 |
| Merck | 55 | $661 |
| GSK | 22 | $519 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $436 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $333 |
| Astellas Pharma US Inc | 14 | $328 |
| Boehringer Ingelheim | 12 | $237 |
| Sanofi-aventis U.S. LLC | 9 | $175 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| Kowa Pharmaceuticals America, Inc. | 13 | $164 |
| Novartis | 10 | $162 |
| Teva Pharmaceuticals USA, Inc. | 9 | $144 |
| Bausch Health US, LLC | 9 | $138 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $128 |
| Abbott | 7 | $123 |
| Eisai Inc. | 5 | $102 |
| Johnson & Johnson | 5 | $97 |
| Biohaven Pharmaceuticals, Inc. | 3 | $67 |
| Lundbeck LLC | 3 | $52 |
| Upsher-smith Laboratories LLC | 2 | $44 |
| Exact Sciences | 2 | $37 |
| Bayer | 2 | $36 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Nevro Corp. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Circassia Inc. | 1 | $16 |
| Vistapharm, Inc. | 1 | $14 |
| Medicure Pharma Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,226 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $54,080 |
| JardianceEmpagliflozin | 42 | $53,515 |
| OzempicSemaglutide | 18 | $39,969 |
| TrulicityDulaglutide | 22 | $37,125 |
| FarxigaDapagliflozin Propanediol | 30 | $36,742 |
| XareltoRivaroxaban | 25 | $26,463 |
| JanuviaSitagliptin Phosphate | 19 | $24,650 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $23,610 |
| MounjaroTirzepatide | 19 | $20,594 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $18,947 |
| Repatha SureclickEvolocumab | 11 | $14,445 |
| MyrbetriqMirabegron | 17 | $11,979 |
| VascepaIcosapent Ethyl | 22 | $10,008 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $8,998 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $237 | $60,83856 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $882 | $57,71941 claims |
| PfizerEliquis | $963 | $54,08046 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $519 | $50,31466 claims |
| Novo NordiskOzempic | $1,900 | $39,96918 claims |
| AstraZenecaFarxiga | $840 | $36,74230 claims |
| Johnson & JohnsonXarelto | $97 | $26,46325 claims |
| MerckJanuvia | $661 | $24,65019 claims |
| Astellas Pharma US IncMyrbetriq | $328 | $11,97917 claims |
| AbbVieSynthroid | $1,296 | $7,01689 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Eagleville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.